Wall Street analysts expect that Mersana Therapeutics Inc (NASDAQ:MRSN) will announce earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mersana Therapeutics’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.39). Mersana Therapeutics posted earnings of ($0.75) per share in the same quarter last year, which suggests a positive year over year growth rate of 50.7%. The business is scheduled to announce its next earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Mersana Therapeutics will report full-year earnings of ($0.62) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.38). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.84) to ($1.20). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $1.08 million. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%.
NASDAQ:MRSN traded down $0.01 during trading hours on Thursday, reaching $1.65. The company had a trading volume of 108,190 shares, compared to its average volume of 413,895. The business’s 50-day simple moving average is $1.82 and its two-hundred day simple moving average is $3.61. Mersana Therapeutics has a twelve month low of $1.40 and a twelve month high of $8.71. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06.
Several hedge funds and other institutional investors have recently modified their holdings of MRSN. Marshall Wace LLP bought a new position in Mersana Therapeutics during the 1st quarter valued at $141,000. Sphera Funds Management LTD. purchased a new stake in shares of Mersana Therapeutics during the first quarter worth $1,052,000. Acadian Asset Management LLC purchased a new stake in shares of Mersana Therapeutics during the second quarter worth $204,000. Russell Investments Group Ltd. increased its position in Mersana Therapeutics by 41.8% during the second quarter. Russell Investments Group Ltd. now owns 13,900 shares of the company’s stock worth $56,000 after buying an additional 4,100 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in Mersana Therapeutics during the second quarter worth $397,000. Hedge funds and other institutional investors own 83.57% of the company’s stock.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Further Reading: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.